NeuroPace (NPCE) Capital Expenditures Growth (1y) (2021 - 2026)
NeuroPace (NPCE) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 15.89% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -11.95% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -47.73% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 106.98% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | NeuroPace | 494.96 Mn | 440.98 Mn | 18.05 Mn | 216.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 216.22% |
| Dec 31, 2025 | 139.11% |
| Sep 30, 2025 | -70.00% |
| Jun 30, 2025 | 50.00% |
| Mar 31, 2025 | -32.73% |
| Dec 31, 2024 | -875.00% |
| Sep 30, 2024 | 1,011.11% |
| Mar 31, 2024 | -58.33% |
| Dec 31, 2023 | -68.63% |
| Sep 30, 2023 | -70.97% |
| Mar 31, 2023 | 325.81% |
| Dec 31, 2022 | -64.46% |
| Sep 30, 2022 | -31.11% |
| Jun 30, 2022 | 744.23% |
| Dec 31, 2021 | 362.90% |
| Sep 30, 2021 | 381.25% |